Arrow keys move between marks; Enter selects; F opens full screen.

Skip to content
Procura
Get started

Cocrystal Pharma, Inc. Federal Contracts

Correct this listing

UEIUEI: the 12-character ID the government gives every company registered for federal work. It replaced the DUNS number in April 2022. Glossary UY8UDESGRJ17· CAGECAGE code: a 5-character code that identifies one company location for federal work. A company with several sites can have several. Glossary 7SGF5· BOTHELL, WA· Active registration until Dec 11, 2026· www.cocrystalpharma.com (opens in a new tab)

Overview

Buyers and offices that award Cocrystal Pharma prime contracts, US$, active FY2021–FY2026

Obligated since award on contracts active FY2021–FY2026

Click a company to open its profile.

Buyers (sub-agency)OfficesThis companyNational Institutes ofHealth$498KNATIONAL INSTITUTES OF HEALTH NIAID(75N930)$498K · National Institutes of Health off…Cocrystal Pharma, Inc.$498K
Awards toSubcontracts toCircle area = dollars

Insight NATIONAL INSTITUTES OF HEALTH NIAID (75N930) is its largest buyer. See more on the Buyers tab

1 buying office

Prime contract obligationsObligation: money the government has legally committed to a contract. It is not the same as money paid. Example: $6M obligated of a $10M ceiling. Glossary, FY2025–FY2026

$498K

About

From the company's SBA profile, updated Dec 2025

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and clinical advancement of innovative antiviral therapeutics for serious and chronic viral diseases. The company employs a proprietary structure-based drug discovery platform supported by Nobel Prize–winning scientific expertise to design first- and best-in-class small-molecule antivirals that target highly conserved viral replication enzymes. This approach enables efficient identification, optimization, and development of broad-spectrum antiviral drug candidates. Cocrystal Pharma’s pipeline includes clinical and preclinical programs addressing influenza, norovirus, coronaviruses including SARS-CoV-2, hepatitis C, and other high-priority viral pathogens. The company has successfully advanced multiple programs through Phase 1 and Phase 2 clinical trials and collaborates with government agencies and global pharmaceutical partners to address critical public health needs.

Prime contract obligations by fiscal year, US$, FY2025–FY2026

Agencies report with a delay; the latest year will rise

Hover over a year to see its value.

FY25$498K

Insight Largest year: $498K in FY2025. See more on the Contracts tab

Prime obligations since award by state of performance, US$, contracts active FY2021–FY2026

Click a state to open its page.

AKMEVTNHWAIDMTNDMNILWIMINYRIMAORNVWYSDIAINOHPANJCTCAUTCONEMOKYWVVAMDDEAZNMKSARTNNCSCDCOKLAMSALGAHITXFLPR
  1. Washington$498K · 100%
Circle area = dollarsOutlined: head office state (Washington)

Insight 100% was performed in Washington. See more on the Contracts tab